Semi-Supervised Multimodal Relevance Vector Regression Improves Cognitive Performance Estimation from Imaging and Biological Biomarkers
- 1.1k Downloads
Accurate estimation of cognitive scores for patients can help track the progress of neurological diseases. In this paper, we present a novel semi-supervised multimodal relevance vector regression (SM-RVR) method for predicting clinical scores of neurological diseases from multimodal imaging and biological biomarker, to help evaluate pathological stage and predict progression of diseases, e.g., Alzheimer’s diseases (AD). Unlike most existing methods, we predict clinical scores from multimodal (imaging and biological) biomarkers, including MRI, FDG-PET, and CSF. Considering that the clinical scores of mild cognitive impairment (MCI) subjects are often less stable compared to those of AD and normal control (NC) subjects due to the heterogeneity of MCI, we use only the multimodal data of MCI subjects, but no corresponding clinical scores, to train a semi-supervised model for enhancing the estimation of clinical scores for AD and NC subjects. We also develop a new strategy for selecting the most informative MCI subjects. We evaluate the performance of our approach on 202 subjects with all three modalities of data (MRI, FDG-PET and CSF) from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. The experimental results show that our SM-RVR method achieves a root-mean-square error (RMSE) of 1.91 and a correlation coefficient (CORR) of 0.80 for estimating the MMSE scores, and also a RMSE of 4.45 and a CORR of 0.78 for estimating the ADAS-Cog scores, demonstrating very promising performances in AD studies.
KeywordsAlzheimer’s disease (AD) Mild cognitive impairment (MCI) Semi-supervised learning Relevance vector regression (RVR) Multimodality
Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc, Inc., as well as non-profit partners the Alzheimer’s Association and Alzheimer’s Drug Discovery Foundation, with participation from the U.S. Food and Drug Administration. Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles.
This work was supported in part by NIH grants EB006733, EB008374, EB009634, and AG041721, by NSFC grants 61075010 and 61170151, by SRFDP grant 20123218110009, by Qing Lan Project, and also by The National Basic Research Program of China (973 Program) grant No. 2010CB732505.
- Belkin, M., Niyogi, P., & Sindhwani, V. (2006). Manifold regularization: a geometric framework for learning from labeled and unlabeled examples. Journal of Machine Learning Research, 7, 2399–2434.Google Scholar
- Chetelat, G., Eustache, F., Viader, F., De la Sayette, V., Pelerin, A., Mezenge, F., et al. (2005). FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase, 11, 14–25.PubMedCrossRefGoogle Scholar
- Drzezga, A., Lautenschlager, N., Siebner, H., Riemenschneider, M., Willoch, F., Minoshima, S., et al. (2003). Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. European Journal of Nuclear Medicine and Molecular Imaging, 30, 1104–1113.PubMedCrossRefGoogle Scholar
- Fan, Y., Kaufer, D., Shen, D., (2010). Joint estimation of multiple clinical variables of neurological diseases from imaging patterns. In Proceedings of 2010 IEEE International Symposium on Biomedical Imaging: From Nano to Macro (ISBI 2010), 852–855.Google Scholar
- Geroldi, C., Rossi, R., Calvagna, C., Testa, C., Bresciani, L., Binetti, G., et al. (2006). Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment. Journal of Neurology, Neurosurgery, and Psychiatry, 77, 1219–1222.PubMedCrossRefGoogle Scholar
- Hinrichs, C., Singh, V., Xu, G., & Johnson, S. (2009b). MKL for robust multi-modality AD classification. Medical Image Computing and Computer Assisted Intervention, 12, 786–794.Google Scholar
- Rakotomamonjy, A., Bach, F. R., Canu, S., & Grandvalet, Y. (2008). SimpleMKL. Journal of Machine Learning Research, 9, 2491–2521.Google Scholar
- Reiman, E. M., Chen, K. W., Liu, X. F., Bandy, D., Yu, M. X., Lee, W. D., et al. (2009). Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease. Proceedings of the National Academy of Sciences of the United States of America, 106, 6820–6825.PubMedCrossRefGoogle Scholar
- Tipping, M. E. (2001). Sparse Bayesian learning and the relevance vector machine. Journal of Machine Learning Research, 1, 211–244.Google Scholar
- Walhovd, K. B., Fjell, A. M., Brewer, J., McEvoy, L. K., Fennema-Notestine, C., Hagler, D. J., Jr., et al. (2010). Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR. American Journal of Neuroradiology, 31, 347–354.PubMedCrossRefGoogle Scholar
- Xu, Z., Jin, R., Yang, H., King, I., Lyu, M. R. (2010). Simple and Efficient Multiple Kernel Learning by Group Lasso. In Proceedings of the 27th Conference on Machine Learning (ICML 2010).Google Scholar
- Zhang, D., & Shen, D. (2011). Semi-supervised multimodal classification of Alzheimer’s disease. In Proceedings of 2011 IEEE International Symposium on Biomedical Imaging: From Nano to Macro (ISBI 2011), 1628–1631.Google Scholar